Table 1.
Baseline Characteristics
| All | not pre-exposed to prophylactic drugs | pre-exposed to prophylactic drugs | |
|---|---|---|---|
| N | 1840 (100%) | 542 (100%) | 1298 (100%) |
| Demographics | |||
| Median age [interquartile range] | 73.0 [61.5; 82.0] | 61.0 [53.0; 73.0] | 76.0 [67.0; 84.0] |
| Female sex | 654 (35.5%) | 157 (29.0%) | 497 (38.3%) |
| Living in French/Italian speaking cantons (vs. Swiss German) | 466 (25.3%) | 136 (25.1%) | 330 (25.4%) |
| Living in urban region (vs. rural/suburban) | 1391 (75.6%) | 413 (76.2%) | 978 (75.3%) |
| Insurance Characteristics | |||
| Annual deductible > 500 Swiss Francs | 240 (13.0%) | 147 (27.1%) | 93 (7.2%) |
| Having supplementary insurance | 1408 (76.5%) | 398 (73.4%) | 1010 (77.8%) |
| Having a managed care contract | 741 (40.3%) | 253 (46.7%) | 488 (37.6%) |
| Prior medication use for chronic co-morbidities | |||
| Cancer | 33 (1.8%) | 7 (1.3%) | 26 (2.0%) |
| Cardiovascular diseases | 1361 (74.0%) | 63 (11.6%) | 1298 (100.0%) |
| Type 1 or type 2 diabetes | 382 (20.8%) | 39 (7.2%) | 343 (26.4%) |
| Hypertension | 709 (38.5%) | 48 (8.9%) | 661 (50.9%) |
| Median number of chronic comorbidities [interquartile range] | 3.0 [2.0; 3.0] | 3.0 [2.0; 3.0] | 3.0 [3.0; 3.0] |
| High-intensity statin use prior index date | 694 (37.7%) | 45 (8.3%) | 649 (50.0%) |
| Inpatient stays prior to index date | 428 (23.3%) | 50 (9.2%) | 378 (29.1%) |
| High outpatient medication costs prior to index date | 154 (8.4%) | 24 (4.4%) | 130 (10.0%) |
| Treatments received within 30 days after index date | |||
| Aspirin | 1212 (65.9%) | 455 (83.9%) | 757 (58.3%) |
| P2Y12 inhibitors | 1191 (64.7%) | 406 (74.9%) | 785 (60.5%) |
| ACE/ARB | 1144 (62.2%) | 366 (67.5%) | 778 (59.9%) |
| Betablocker | 1117 (60.7%) | 358 (66.1%) | 759 (58.5%) |
| High-intensity statins | 990 (53.8%) | 386 (71.2%) | 604 (46.5%) |
| Combination treatments received | |||
| Three drug classesa | 486 (26.4%) | 161 (29.7%) | 325 (25.0%) |
| Four drug classesa | 595 (32.3%) | 236 (43.5%) | 359 (27.7%) |
| Clinical outcomes 390 days after index date (30 day assessment period and 360 day outcome observation period) | |||
| Having died after index date | 175 (9.5%) | 24 (4.4%) | 151 (11.6%) |
| Having had inpatient hospital stays after index date | 735 (39.9%) | 146 (26.9%) | 589 (45.4%) |
a Four class treatments include high intensity statins, beta-blockers, ACE/ARB and either Aspirin or P2Y12 inhibitors. Three class treatments only include three of the four drug classes